ResearcherDartmouth–Hitchcock Medical CenterNo recent work listed
Charles R. Thomas
Matched on ORCID iD 0009-0005-2278-1818; OpenAlex author ID A5106353859. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper
Papers 3
- Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic… Co-author DOI 10.1002/cam4.5971↗
- Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasin… Co-author DOI 10.3390/cancers14030609↗
- Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. Last author DOI 10.3322/caac.21626↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Aaron J. Grossberg · 3 shared papers, 2020–2023 · strength 0.37
- Paper Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderlin… DOI 10.1002/cam4.5971↗
- Paper Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resectio… DOI 10.3390/cancers14030609↗
- Paper Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. DOI 10.3322/caac.21626↗
- Brett C. Sheppard · 2 shared papers, 2022–2023 · strength 0.26
- Paper Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderlin… DOI 10.1002/cam4.5971↗
- Paper Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resectio… DOI 10.3390/cancers14030609↗
- Skye C. Mayo · 2 shared papers, 2022–2023 · strength 0.26
- Paper Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderlin… DOI 10.1002/cam4.5971↗
- Paper Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resectio… DOI 10.3390/cancers14030609↗
- Adel Kardosh · 2 shared papers, 2022–2023 · strength 0.26
- Paper Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderlin… DOI 10.1002/cam4.5971↗
- Paper Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resectio… DOI 10.3390/cancers14030609↗
- Emerson Yu-sheng Chen · 2 shared papers, 2022–2023 · strength 0.26
- Paper Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderlin… DOI 10.1002/cam4.5971↗
- Paper Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resectio… DOI 10.3390/cancers14030609↗
- Charles D. Lopez · 2 shared papers, 2022–2023 · strength 0.26
- Paper Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderlin… DOI 10.1002/cam4.5971↗
- Paper Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resectio… DOI 10.3390/cancers14030609↗
- Christopher R. Deig · 2 shared papers, 2020–2022 · strength 0.22
- Gina M. Vaccaro · 1 shared paper, 2023 · strength 0.15
- Ali Noel Gunesch · 1 shared paper, 2022 · strength 0.11
- Thomas Lee Sutton · 1 shared paper, 2022 · strength 0.11
- William L. Hwang · 1 shared paper, 2020 · strength 0.10
- Arnav Mehta · 1 shared paper, 2020 · strength 0.10
- Diane M. Simeone · 1 shared paper, 2020 · strength 0.10
- Anirban Maitra · 1 shared paper, 2020 · strength 0.10
- Daniel L. Marks · 1 shared paper, 2020 · strength 0.10
- Colin D. Weekes · 1 shared paper, 2020 · strength 0.10
- Linda Chi Hang Chu · 1 shared paper, 2020 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.